Tempest Therapeutics’ (TPST) Outperform Rating Reiterated at William Blair

William Blair reissued their outperform rating on shares of Tempest Therapeutics (NASDAQ:TPST) in a research report sent to investors on Wednesday morning,RTT News reports.

Separately, HC Wainwright restated a “buy” rating and issued a $47.00 target price on shares of Tempest Therapeutics in a report on Wednesday. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tempest Therapeutics has an average rating of “Buy” and an average price target of $20.00.

Tempest Therapeutics Price Performance

Shares of Tempest Therapeutics stock opened at $0.89 on Wednesday. The business has a 50 day simple moving average of $1.20 and a two-hundred day simple moving average of $1.95. The stock has a market capitalization of $22.43 million, a P/E ratio of -0.58 and a beta of -1.78. Tempest Therapeutics has a 12 month low of $0.83 and a 12 month high of $6.00.

Hedge Funds Weigh In On Tempest Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC lifted its stake in Tempest Therapeutics by 69.2% during the first quarter. Virtu Financial LLC now owns 28,574 shares of the company’s stock worth $112,000 after purchasing an additional 11,689 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in Tempest Therapeutics during the 2nd quarter worth about $55,000. Fullcircle Wealth LLC purchased a new position in Tempest Therapeutics during the 3rd quarter valued at about $87,000. Empower Advisory Group LLC acquired a new position in Tempest Therapeutics in the 3rd quarter valued at about $49,000. Finally, XTX Topco Ltd purchased a new stake in Tempest Therapeutics during the third quarter worth about $34,000. Hedge funds and other institutional investors own 22.52% of the company’s stock.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.